Form 4: Karyopharm Therapeutics Director Acquires 69,000 Stock Options
SEC Form 4 Filing
Christy J. Oliger, a director of Karyopharm Therapeutics Inc., acquired 69,000 nonstatutory stock options on May 29, 2024.
Summary
- Christy J. Oliger, a director of Karyopharm Therapeutics Inc., filed a Form 4 to report changes in beneficial ownership.
- On May 29, 2024, Oliger acquired 69,000 nonstatutory stock options with an exercise price of $0.96.
- These options vest 100% on May 29, 2025, and expire on May 28, 2034.
- Following the transaction, Oliger directly owns 69,000 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing indicating a director's acquisition of stock options, which can be seen as a positive sign of confidence but doesn't necessarily indicate a major shift in the company's prospects.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation.
Key Dates
| Date | Description |
|---|---|
| 05/29/2024 | Date of transaction: Christy J. Oliger acquired 69,000 nonstatutory stock options. |
| 05/29/2025 | Vesting date: 100% of the acquired stock options vest. |
| 05/28/2034 | Expiration date: The acquired stock options expire. |
| 05/30/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.